Christopher Berger • UCSF Profiles (original) (raw)

  1. Use of a digital adherence technology to support TB treatment among adolescents. Int J Tuberc Lung Dis. 2025 Aug 29; 29(9):404-409. Schraufnagel AM, Crowder R, Wambi P, Nakasendwa S, Kityamuwesi A, Jaganath D, Musoke M, Nannozi J, Waswa J, Sanyu AN, Lamunu M, Twinamasiko A, Tinka LK, Oyuku D, Babirye D, Berger C, Thompson R, Turyahabwe S, Dowdy D, Katamba A, Cattamanchi A, Kiwanuka N. PMID: 40883883.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  2. Scale-up of 99DOTS for TB treatment supervision: an interrupted time series analysis. Int J Tuberc Lung Dis. 2025 Jun 27; 29(7):306-311. Crowder R, Nakasendwa S, Kityamuwesi A, Musoke M, Nannozi J, Waswa J, Sanyu AN, Lamunu M, Twinamasiko A, Tinka LK, Oyuku D, Babirye D, Berger C, Thompson R, Turyahabwe S, Dowdy D, Katamba A, Cattamanchi A, Kiwanuka N. PMID: 40579762.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  3. Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment. J Int AIDS Soc. 2024 Dec; 27(12):e26390. Aschmann HE, Musinguzi A, Kadota JL, Namale C, Kakeeto J, Nakimuli J, Akello L, Welishe F, Nakitende A, Berger C, Dowdy DW, Cattamanchi A, Semitala FC, Kerkhoff AD. PMID: 39587885; PMCID: PMC11589386.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  4. Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda. Open Forum Infect Dis. 2024 Nov; 11(11):ofae667. Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PPJ, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. PMID: 39582503; PMCID: PMC11584509.
    View in: PubMed Mentions: 1
  5. Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial. PLOS Glob Public Health. 2024; 4(10):e0003347. Musinguzi A, Kasidi JR, Kadota JL, Welishe F, Nakitende A, Akello L, Nakimuli J, Kunihira LT, Opira B, Baik Y, Patel D, Sammann A, Berger CA, Aschmann HE, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC, Katahoire AR. PMID: 39446746; PMCID: PMC11500930.
    View in: PubMed Mentions: 1
  6. Impact of heteroresistance on treatment outcomes of people with drug-resistant TB. IJTLD Open. 2024 Oct; 1(10):466-472. Crowder R, Kato-Maeda M, Schwem B, Dela Tonga A, Geocaniga-Gaviola DM, Lopez E, Valdez CL, Lim AR, Hunat N, Sedusta AG, Sacopon CA, Atienza GAM, Bulag E, Lim D, Bascuña J, Shah K, Basillio RP, Berger CA, Lopez MCDP, Sen S, Allender C, Folkerts M, Karaoz U, Brodie E, Mitarai S, Garfin AMC, Ama MC, Engelthaler DM, Cattamanchi A, Destura R. PMID: 39398438; PMCID: PMC11467852.
    View in: PubMed Mentions: 1
  7. Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial. medRxiv. 2024 Aug 22. Musinguzi A, Kasidi JR, Kadota JL, Welishe F, Nakitende A, Akello L, Nakimuli J, Kunihira LT, Opira B, Baik Y, Patel D, Sammann A, Berger CA, Aschmann HE, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC, Katahoire AR. PMID: 39314926; PMCID: PMC11419250.
    View in: PubMed Mentions:
  8. Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda. medRxiv. 2024 Aug 09. Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PP, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. PMID: 39148841; PMCID: PMC11326332.
    View in: PubMed Mentions:
  9. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb; 21(2):e1004356. Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 38377166; PMCID: PMC10914279.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  10. Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda. IJTLD Open. 2024 Feb; 1(2):83-89. Musinguzi A, Aschmann HE, Kadota JL, Nakimuli J, Welishe F, Kakeeto J, Namale C, Akello L, Nakitende A, Berger C, Katamba A, Tumuhamye J, Kiwanuka N, Dowdy DW, Cattamanchi A, Semitala FC. PMID: 38966690; PMCID: PMC11221590.
    View in: PubMed Mentions: 3
  11. Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. PLOS Digit Health. 2023 Jun; 2(6):e0000138. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger CA, Lamunu M, Namale C, Kunihira Tinka L, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Patel D, Sammann A, Turyahabwe S, Dowdy DW, Katamba A, Cattamanchi A. PMID: 37390077; PMCID: PMC10313004.
    View in: PubMed Mentions: 5
  12. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda. Int J Tuberc Lung Dis. 2023 06 01; 27(6):458-464. Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. PMID: 37231600; PMCID: PMC10316532.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  13. Barriers and Facilitators to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in Uganda: Qualitative Study. J Med Internet Res. 2023 05 30; 25:e38828. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, Crowder R, Turyahabwe S, Katamba A, Cattamanchi A. PMID: 37252774; PMCID: PMC10265431.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  14. Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines. PLoS One. 2022; 17(11):e0277078. Huddart S, Geocaniga-Gaviola DM, Crowder R, Lim AR, Lopez E, Valdez CL, Berger CA, Destura R, Kato-Maeda M, Cattamanchi A, Garfin AMC. PMID: 36346814; PMCID: PMC9642894.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  15. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 34914696; PMCID: PMC8726462.
    View in: PubMed Mentions: 14 Fields:
    Translation:Humans
  16. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun. 2021 Jun 30; 2(1):71. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. PMID: 34193311; PMCID: PMC8247167.
    View in: PubMed Mentions: 17
  17. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLoS Med. 2021 05; 18(5):e1003628. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A. PMID: 33956802; PMCID: PMC8136841.
    View in: PubMed Mentions: 28 Fields:
    Translation:Humans
  18. Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR Form Res. 2020 Dec 08; 4(12):e19270. Patel D, Berger CA, Kityamuwesi A, Ggita J, Kunihira Tinka L, Turimumahoro P, Feler J, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33289494; PMCID: PMC7755538.
    View in: PubMed Mentions: 10 Fields:
  19. Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. BMJ Open. 2020 11 27; 10(11):e039895. Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger CA, Tucker A, Patel D, Sammann A, Dowdy D, Stavia T, Cattamanchi A, Katamba A. PMID: 33247012; PMCID: PMC7703448.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  20. Opportunities to improve digital adherence technologies and TB care using human-centered design. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1112-1115. Berger C, Patel D, Kityamuwesi A, Ggita J, Tinka LK, Turimumahoro P, Neville K, Chehab L, Chen AZ, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. PMID: 33126949; PMCID: PMC9094398.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  21. Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Dec; 21:100184. Berger CA, Kityamuwesi A, Crowder R, Lamunu M, Kunihira Tinka L, Ggita J, Sanyu Nakate A, Namale C, Oyuku D, Chen K, Turyahabwe S, Cattamanchi A, Katamba A. PMID: 33204851; PMCID: PMC7648165.
    View in: PubMed Mentions: 8
  22. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. PMID: 32787925; PMCID: PMC7425004.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansCTClinical Trials
  23. Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis. Ann Am Thorac Soc. 2020 08; 17(8):911-917. Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C. PMID: 32464069.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  24. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020 07 01; 24(7):729-731. Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, Berger CA, Kamya MR, Namusobya J, Semitala FC, Cattamanchi A, Dowdy DW. PMID: 32718409; PMCID: PMC7891860.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  25. Management and Outcomes of Critically-III Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series. medRxiv. 2020 May 29. Vanderburg S, Alipanah N, Crowder R, Yoon C, Wang R, Thakur N, Slown K, Shete PB, Rofael M, Metcalfe JZ, Merrifield C, Marquez C, Malcolm K, Lipnick M, Jain V, Gomez A, Burns G, Brown LB, Berger C, Auyeung V, Cattamanchi A, Hendrickson CM. PMID: 32511538; PMCID: PMC7273306.
    View in: PubMed Mentions:
  26. Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. Int J Infect Dis. 2020 Jul; 96:276-283. Chaka W, Berger C, Huo S, Robertson V, Tachiona C, Magwenzi M, Magombei T, Mpamhanga C, Katzenstein D, Metcalfe J. PMID: 32289564; PMCID: PMC8040698.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  27. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis. 2020 Feb; 18:100136. Cattamanchi A, Berger CA, Shete PB, Turyahabwe S, Joloba M, Moore DA, Davis LJ, Katamba A. PMID: 31879703; PMCID: PMC6920311.
    View in: PubMed Mentions: 17
  28. Open-source point-of-care electronic medical records for use in resource-limited settings: systematic review and questionnaire surveys. BMJ Open. 2012; 2(4). Millard PS, Bru J, Berger CA. PMID: 22763661; PMCID: PMC3391372.
    View in: PubMed Mentions: 14 Fields:

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs